Lotilaner
 | |
| Clinical data | |
|---|---|
| Trade names | Credelio, Xdemvy |
| Other names | TP-03 |
| License data | |
| Routes of administration | By mouth, eye drops |
| Drug class | Antiparasitic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H14Cl3F6N3O3S |
| Molar mass | 596.75 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lotilaner, sold under the brand name Xdemvy, is a medication used for the treatment of Demodex blepharitis.[1][5] It is used as an eye drop.[1]
Lotilaner is an ectoparasiticide (anti-parasitic).[1]
It was approved for medical use in the United States in July 2023.[1][5][6][7]
Medical uses
Lotilaner is indicated for the treatment of Demodex blepharitis.[1]
Veterinary uses
Lotilaner, sold under the brand name Credelio among others, is a veterinary medication used to control fleas and ticks in dogs and cats.[2][3][4][8] It is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and for the treatment and control of tick infestations including lone star tick (Amblyomma americanum), American dog tick (Dermacentor variabilis), black-legged tick (Ixodes scapularis), and brown dog tick (Rhipicephalus sanguineus).[9]
Lotilaner in combination with milbemycin oxime is sold under the brand name Credelio Plus.[10] It is used in dogs to treat concurrent infestations with parasites living outside (ticks and/or fleas) and inside (worms) the animal's body.[10]
References
- ^ a b c d e f "Xdemvy (lotilaner ophthalmic solution) 0.25%, for topical ophthalmic use" (PDF). Archived (PDF) from the original on 27 July 2023. Retrieved 6 August 2023.
- ^ a b "Credelio- lotilaner tablet, chewable". DailyMed. Archived from the original on 5 August 2021. Retrieved 4 August 2021.
- ^ a b "Credelio- lotilaner tablet, chewable". DailyMed. Archived from the original on 5 August 2021. Retrieved 4 August 2021.
- ^ a b "Credelio EPAR". European Medicines Agency. Archived from the original on 27 January 2022. Retrieved 4 August 2021.
- ^ a b "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 25 July 2023. Archived from the original on 21 January 2023. Retrieved 5 August 2023.
- ^ "Xdemvy: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 27 July 2023. Retrieved 5 August 2023.
- ^ "FDA Approves Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis" (Press release). Tarsus Pharmaceuticals. 25 July 2023. Retrieved 5 August 2023 – via GlobeNewswire.
- ^ Kuntz EA, Kammanadiminti S (November 2017). "Safety evaluation of lotilaner in dogs after oral administration as flavoured chewable tablets (Credelio)". Parasites & Vectors. 10 (1): 538. doi:10.1186/s13071-017-2468-y. PMC 5664904. PMID 29089043.
- ^ "Freedom Of Information Summary, Supplemental New Animal Drug Application, NADA 141-494, Credelio, Lotilaner, Chewable Tablets, Dogs". 3 September 2019. Archived from the original on 18 May 2022. Retrieved 1 December 2019.
- ^ a b "Credelio Plus EPAR". European Medicines Agency. 19 February 2021. Archived from the original on 7 December 2022. Retrieved 4 August 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |